These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23039309)

  • 21. Richter's syndrome: Novel and promising therapeutic alternatives.
    Rossi D
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):30-39. PubMed ID: 27742070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.
    Nagel S; Venturini L; Meyer C; Kaufmann M; Scherr M; Drexler HG; Macleod RA
    Leuk Lymphoma; 2011 Feb; 52(2):290-7. PubMed ID: 21261500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex.
    Wu S; Peña A; Korcz A; Soprano DR; Soprano KJ
    Oncogene; 1996 Feb; 12(3):621-9. PubMed ID: 8637719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic lymphocytic leukemia and the Warburg effect.
    Moreno C
    Blood; 2015 May; 125(22):3368-9. PubMed ID: 26022050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
    Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT
    Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma.
    Moore AM; Moshkin O; Swain GJ; Crocker S; LeBrun DP
    Diagn Pathol; 2018 May; 13(1):34. PubMed ID: 29793519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitor of differentiation 1 transcription factor promotes metabolic reprogramming in hepatocellular carcinoma cells.
    Sharma BK; Kolhe R; Black SM; Keller JR; Mivechi NF; Satyanarayana A
    FASEB J; 2016 Jan; 30(1):262-75. PubMed ID: 26330493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-myc activation by proviral insertion in MCF 247-induced murine T-cell lymphomas.
    Dolcetti R; Rizzo S; Viel A; Maestro R; De Re V; Feriotto G; Boiocchi M
    Oncogene; 1989 Aug; 4(8):1009-14. PubMed ID: 2548143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression.
    Delpuech O; Griffiths B; East P; Essafi A; Lam EW; Burgering B; Downward J; Schulze A
    Mol Cell Biol; 2007 Jul; 27(13):4917-30. PubMed ID: 17452451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.
    Sharma N; Magistroni V; Piazza R; Citterio S; Mezzatesta C; Khandelwal P; Pirola A; Gambacorti-Passerini C
    Mol Cancer; 2015 Jul; 14():132. PubMed ID: 26179066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rare but recurrent t(8;13)(q24;q14) translocation in B-cell chronic lymphocytic leukaemia causing MYC up-regulation and concomitant loss of PVT1, miR-15/16 and DLEU7.
    Macchia G; Lonoce A; Venuto S; Macrí E; Palumbo O; Carella M; Lo Cunsolo C; Iuzzolino P; Hernández-Sánchez M; Hernandez-Rivas JM; Storlazzi CT
    Br J Haematol; 2016 Jan; 172(2):296-9. PubMed ID: 26010203
    [No Abstract]   [Full Text] [Related]  

  • 32. Cell-cycle progression is not essential for c-Myc to block differentiation.
    Ryan KM; Birnie GD
    Oncogene; 1997 Jun; 14(23):2835-43. PubMed ID: 9190900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney cancer: AR promotes RCC via lncRNA interaction.
    Fenner A
    Nat Rev Urol; 2016 May; 13(5):242. PubMed ID: 27041208
    [No Abstract]   [Full Text] [Related]  

  • 34. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X; Giap C; Lazo JS; Prochownik EV
    Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel MASH1 enhancer with N-myc and CREB-binding sites is active in neuroblastoma.
    Watt F; Watanabe R; Yang W; Agren N; Arvidsson Y; Funa K
    Cancer Gene Ther; 2007 Mar; 14(3):287-96. PubMed ID: 17124508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
    Rao G; Alland L; Guida P; Schreiber-Agus N; Chen K; Chin L; Rochelle JM; Seldin MF; Skoultchi AI; DePinho RA
    Oncogene; 1996 Mar; 12(5):1165-72. PubMed ID: 8649810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
    Matolcsy A; Chadburn A; Knowles DM
    Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q.
    Prieto-Sánchez RM; Hernández JA; García JL; Gutiérrez NC; San Miguel J; Bustelo XR; Hernández JM
    Br J Haematol; 2006 Jun; 133(6):642-5. PubMed ID: 16704440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ.
    Beaulieu ME; McDuff FO; Frappier V; Montagne M; Naud JF; Lavigne P
    J Mol Recognit; 2012 Jul; 25(7):414-26. PubMed ID: 22733550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mmip-2/Rnf-17 enhances c-Myc function and regulates some target genes in common with glucocorticoid hormones.
    Yin XY; Grove LE; Prochownik EV
    Oncogene; 2001 May; 20(23):2908-17. PubMed ID: 11420703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.